Affiliations: Sanders-Brown Center on Aging, University of Kentucky College of Medicine, Lexington, KY, USA
Correspondence:
[*]
Correspondence to: Christopher M. Norris, PhD, Sanders-Brown Center on Aging, University of Kentucky College
of Medicine, 789 South Limestone St, Rm 553, Lexington, KY 40536, USA. E-mail: [email protected].
Abstract: Numerous preclinical and human tissue studies implicate the protein phosphatase calcineurin (CN) as a pathophysiologic mechanism in Alzheimer’s disease (AD) and other neurodegenerative conditions. Using public electronic records of tens of thousands of individuals across the United States, Silva et al. (2023) show that use of the FDA-approved CN inhibitor, tacrolimus (for purposes of immunosuppression) is also associated with reduced prevalence of dementia-related symptoms. Notably, the study controls for age, sex, and race as well as multiple risk factors for AD. The results suggest that tacrolimus, and possibly other immunosuppressants could be repurposed for the treatment of AD-related dementia.
